A141080 Stock Overview
LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LigaChem Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩68,000.00 |
| 52 Week High | ₩84,000.00 |
| 52 Week Low | ₩31,200.00 |
| Beta | 1.01 |
| 1 Month Change | 5.26% |
| 3 Month Change | 44.37% |
| 1 Year Change | 72.59% |
| 3 Year Change | 38.92% |
| 5 Year Change | 158.56% |
| Change since IPO | 677.14% |
Recent News & Updates
Shareholder Returns
| A141080 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 3.8% | 0.5% | 0.8% |
| 1Y | 72.6% | -1.2% | 6.3% |
Return vs Industry: A141080 exceeded the KR Life Sciences industry which returned -1.2% over the past year.
Return vs Market: A141080 exceeded the KR Market which returned 6.3% over the past year.
Price Volatility
| A141080 volatility | |
|---|---|
| A141080 Average Weekly Movement | 11.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A141080's share price has been volatile over the past 3 months.
Volatility Over Time: A141080's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 135 | Yong Kim | www.legochembio.com |
LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules.
LigaChem Biosciences Inc. Fundamentals Summary
| A141080 fundamental statistics | |
|---|---|
| Market cap | ₩2.44t |
| Earnings (TTM) | -₩73.70b |
| Revenue (TTM) | ₩34.15b |
71.6x
P/S Ratio-33.2x
P/E RatioIs A141080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A141080 income statement (TTM) | |
|---|---|
| Revenue | ₩34.15b |
| Cost of Revenue | ₩16.35b |
| Gross Profit | ₩17.80b |
| Other Expenses | ₩91.50b |
| Earnings | -₩73.70b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05k |
| Gross Margin | 52.12% |
| Net Profit Margin | -215.85% |
| Debt/Equity Ratio | 8.0% |
How did A141080 perform over the long term?
See historical performance and comparison